|Bid||0.00 x N/A|
|Ask||0.00 x N/A|
|Day's range||122.42 - 127.65|
|52-week range||122.42 - 127.65|
|Beta (5Y monthly)||2.26|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
- Collaboration leverages expertise and capabilities of both companies towards developing life-changing treatments for severe neurological diseases - ZUG, Switzerland and CAMBRIDGE, Mass. and THOUSAND OAKS, Calif., June 15, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, and Capsida Biotherapeutics Inc., a biotechnology company dedicated to developing breakthrough gene therapi
Shares of the biotech industry leader have taken a big hit thanks to a clinical development pipeline that hasn't produced any big wins lately.
CRISPR Therapeutics' (CRSP) gene-editing therapy, CTX001, shows consistent and sustained response to treatment in patients with transfusion-dependent beta thalassemia and sickle cell disease.